COAG (Hemab Therapeutics Holdings, Inc. Common Stock) Stock Analysis - AI Report
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a publicly traded the market company. As of May 21, 2026, COAG trades at $26.47 with a market cap of $1.27B and a P/E ratio of 0.00. COAG moved +2.40% today. Year to date, COAG is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $23.00 to $36.61. Rallies surfaces COAG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on COAG?
Rallies AI research for COAG combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
RA CAPITAL MANAGEMENT, L.P. bought 6.39K (~$159.04K) on May 12, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 14.15K (~$346.23K) on May 11, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 25.72K (~$643.00K) on May 11, 2026.
COAG Analyst Consensus
COAG analyst coverage data. Average price target: $0.00.
Common questions about COAG
What is the AI research view on COAG?
Rallies AI research for COAG combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for COAG?
Rallies AI research for COAG combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is COAG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for COAG. It does not provide personalized investment advice.
